Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

about

Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland.

P2860

Q54977502-86A257DD-8A01-48A4-9596-04065EA9531C

P2860

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

Item

http://www.wikidata.org/entity/Q40073097

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

@en

type

Item

label

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

@en

prefLabel

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

@en

P1476

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis

@en

P2093

Alexandre Prat

http://www.w3.org/2001/XMLSchema#string

Cameron Shaw

http://www.w3.org/2001/XMLSchema#string

Claudio Solaro

http://www.w3.org/2001/XMLSchema#string

Dana Horakova

http://www.w3.org/2001/XMLSchema#string

Diana Ferraro

http://www.w3.org/2001/XMLSchema#string

Ernest Butler

http://www.w3.org/2001/XMLSchema#string

Eva Havrdova

http://www.w3.org/2001/XMLSchema#string

Francois Grand'Maison

http://www.w3.org/2001/XMLSchema#string

Jeannette Lechner-Scott

http://www.w3.org/2001/XMLSchema#string

Julie Prevost

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Observational data: Understanding the real MS world.

Data quality evaluation for observational multiple sclerosis registries.

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Cladribine (2-chlorodeoxyadenosine)

MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis.

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.

P304

1617-1626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1352458517728812

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28857680

http://www.w3.org/2001/XMLSchema#string

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

about

P2860

P2860

Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698